Wall Street Seeks Detail on Pfizer’s Covid Products Forecast
- Covid vaccine, pill sales each seen below analysts’ estimates
- CEO outlines company’s strategy for outbreak’s endemic phase
Empty Pfizer-BioNTech Covid-19 vaccine vials at a high school vaccination site in Lansdale, Pennsylvania, U.S.
Photographer: Hannah Beier/BloombergThis article is for subscribers only.
Pfizer Inc.’s forecast for record sales in 2022 disappointed investors who wanted more details on the growth outlook for its Covid-19 vaccine and treatment.
The New York-based drugmaker sees revenue as high as $102 billion this year, short of the average analyst estimate of $106 billion. Pfizer said it clinched $32 billion in 2022 contracts for the vaccine, Comirnaty, through late January, and $22 billion for its pill, Paxlovid.